Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00631800 · ClinicalTrials.gov registry record · Phase 2
Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110
A Phase 2 study, sponsored by Biosynexus Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT00631800 is a Phase 2 study that has completed, run by Biosynexus Incorporated. The registered enrollment target is 88 participants.
The verdict
NCT00631800, a Phase 2 study, has completed, sponsored by Biosynexus Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety (including tolerability), pharmacokinetics, pharmacodynamics and clinical activity of BSYX-A110 administered in a 3-dose regimen on Study Days 0, 7, and 14.
Interventions
- DRUG Pagibaximab (formerly BSYX-A110)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2003-05 |
| Est. Completion | 2004-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00631800
The ClinicalTrials.gov registry entry for NCT00631800 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosynexus Incorporated, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pagibaximab (formerly BSYX-A110) is the first listed.
NCT00631800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00631800 about?
NCT00631800 is a clinical study titled "Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110". The purpose of this study is to evaluate the safety (including tolerability), pharmacokinetics, pharmacodynamics and clinical activity of BSYX-A110 administered in a 3-dose regimen on Study Days 0, 7, and 14.
What is the current status of trial NCT00631800?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2003-05. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00631800?
The interventions under investigation include: Pagibaximab (formerly BSYX-A110) (DRUG).
Who is sponsoring clinical trial NCT00631800?
This trial is sponsored by Biosynexus Incorporated, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.